Alpelisib Plus Fulvestrant for PIK3CA-Mutated, Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2-Negative Advanced Breast Cancer: Final Overall Survival Results From SOLAR-1.
Alpelisib Plus Fulvestrant for PIK3CA-Mutated, Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2-Negative Advanced Breast Cancer: Final Overall Survival Results From SOLAR-1.
复制标题
Alpelisib 加氟维司群治疗 PIK3CA 突变、激素受体阳性、人表皮生长因子受体 2 阴性晚期乳腺癌：SOLAR-1 的最终总体生存结果。
作者：
F. André;E. Ciruelos;D. Juric;S. Loibl;M. Campone;I. Mayer;G. Rubovszky;T. Yamashita;B. Kaufman;Yung;K. Inoue;Z. Pápai;M. Takahashi;F. Ghaznawi;D. Mills;M. Kaper;M. Miller;P. Conte;H. Iwata;H. Rugo
DOI：
10.1200/jco.2017.72.7107
发表时间：
2018-05-01
期刊：
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
影响因子：
--
作者：
Juric D;Rodon J;Tabernero J;Janku F;Burris HA;Schellens JHM;Middleton MR;Berlin J;Schuler M;Gil-Martin M;Rugo HS;Seggewiss-Bernhardt R;Huang A;Bootle D;Demanse D;Blumenstein L;Coughlin C;Quadt C;Baselga J
通讯作者：
Baselga J